Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation develops and commercializes ophthalmic pharmaceutical and medical technology products for glaucoma, corneal disorders, and retinal diseases. News about Glaukos regularly covers financial results, global commercial execution, and updates for its dropless platform technologies, including iDose TR for sustained intracameral glaucoma drug delivery and Epioxa for corneal cross-linking in keratoconus.
Recurring company developments include FDA labeling actions for iDose TR, CMS coding and commercial availability updates for Epioxa, scientific presentations in ophthalmology, and quarterly sales trends across its glaucoma franchise. Company background also includes Micro-Invasive Glaucoma Surgery products such as iStent, iStent inject W, and iStent infinite, along with a pipeline aimed at chronic eye diseases.
Glaukos (NYSE:GKOS) will present multiple scientific abstracts and exhibit at the ASCRS Annual Meeting, April 10–13, 2026, in Washington, D.C. The company will staff booth #407 and sponsor an educational symposium introducing Epioxa on April 10, 2026, from 12:00–1:00 p.m. ET.
Presentations cover glaucoma and corneal health, including outcomes for trabecular micro-bypass stents and travoprost intracameral implants, plus posters on corneal cross-linking and device safety.
Glaukos (NYSE: GKOS) announced commercial availability of Epioxa on March 19, 2026, the first FDA‑approved, incision‑free topical drug therapy for keratoconus.
Epioxa is an oxygen‑ and light‑catalyzed topical corneal cross‑linking treatment intended to reduce pain and recovery time versus epithelium‑removing procedures. Orders are available directly from Glaukos and via specialty distributors. The company said it will expand patient awareness, access programs, and financial assistance to address underdiagnosis and undertreatment.
Glaukos (NYSE:GKOS) reported record Q4 2025 net sales of $143.1M (+36% YoY) and full-year 2025 net sales of $507.4M (+32% YoY). The company recorded a one-time $112.9M impairment tied to an acquired intangible asset, driving a GAAP net loss of $187.7M for 2025. Glaukos ended Q4 with $282.6M in cash and no debt, and reaffirmed 2026 net sales guidance of $600M–$620M.
Non-GAAP gross margin remained strong at ~84%, while non-GAAP operating and net losses narrowed versus 2024.
Glaukos (NYSE:GKOS) announced U.S. FDA approval of an NDA labeling supplement dated January 28, 2026 permitting re-administration of iDose TR under a repeat treatment protocol.
The approval follows Glaukos' 2025 supplement and is supported by clinical evidence showing no clinically significant corneal endothelial cell loss through three years and a safe, well-tolerated second administration over 12 months.
Glaukos (NYSE: GKOS) will release its fourth quarter and full year 2025 financial results after market close on February 17, 2026. Management will discuss results in a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 17, 2026. A live webcast link will be available at the company's investor website.
To join the call dial 800-715-9871 (U.S.) or 646-307-1963 (International) and enter Conference ID 5255602. A replay will be archived on the investor website after the call.
Glaukos (NYSE: GKOS) reported preliminary, unaudited net sales of approximately $143 million for Q4 2025 (up 36% year-over-year) and approximately $507 million for full year 2025 (up 32% year-over-year). Q4 sales mix: U.S. Glaucoma $86M (iDose TR $45M), International Glaucoma $33M, Corneal Health $24M. Full year mix: U.S. Glaucoma $299M (iDose TR $136M), International Glaucoma $122M, Corneal Health $86M. The company ended Q4 with approximately $283M in cash, cash equivalents and short-term investments and no debt. Glaukos reaffirmed 2026 net sales guidance of $600M–$620M. Preliminary results are subject to revision when final results are released after market close on Feb 17, 2026, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET.
Glaukos (NYSE:GKOS) said its management will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 4:30 p.m. PT in San Francisco.
A live and archived webcast will be available in the Investors section of the company website for viewers who cannot attend in person.
Glaukos (NYSE:GKOS) said its management will participate in multiple investor conferences in November–December 2025, including UBS Global Healthcare (Nov 11, 2025, 10:15 a.m. ET, Palm Beach), Stifel Healthcare (Nov 12, 2025, 1:20 p.m. ET, New York), Stephens Annual Investment (Nov 18, 2025, 10:00 a.m. CT, Nashville), BTIG Ophthalmology Day (Dec 1, 2025, virtual) and Citi Global Healthcare (Dec 3, 2025, 1:45 p.m. ET, Miami).
A live and archived webcast for applicable events will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
Glaukos (NYSE: GKOS) reported record Q3 2025 net sales of $133.5M, up 38% YoY (37% constant currency), driven by glaucoma sales of $110.2M (+45% YoY) and U.S. glaucoma sales of $80.8M (+57% YoY). Gross margin was ~78% and non-GAAP gross margin ~84% for Q3 2025. GAAP net loss was $16.2M (loss of $0.28 per diluted share); non-GAAP net loss was $9.2M (loss of $0.16 per diluted share). Cash and equivalents plus short-term investments totaled ~$277.5M and the company reported no debt. Management raised 2025 net sales guidance to $490M–$495M and provided preliminary 2026 net sales guidance of $600M–$620M.
Glaukos (NYSE:GKOS) announced FDA approval of Epioxa HD / Epioxa, the first FDA‑approved incision‑free topical drug therapy for keratoconus, a rare sight‑threatening corneal disease. Approval was supported by two randomized, double‑masked Phase 3 trials that randomized over 400 patients and met primary efficacy endpoints with favorable tolerability. Epioxa uses sequential topical formulations activated by UV in an oxygen‑enriched environment to perform corneal cross‑linking without removing the epithelium. Glaukos expects commercial availability in Q1 2026 and plans investments in patient awareness, access programs, and co‑pay assistance.